Journals / MN Oftalmoloji / 2016 / Cilt: 23 - Sayı: 1

Topical Cyclosporine in The Treatment of Dry Eye

Kuru Göz Tedavisinde Topikal Siklosporin Kullanımı

Pages
32–39
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

There isa need for better designed randomized placebo controlled double-blinded studies in order to find out the type of dry eye inwhich topical cyclosporine is the most effective, optimum dose, and treatment duration

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Cyclosporine has been used successfully as a systemic immunomodulator for more than twenty years. 0.05% topical formulation has been approved by FDA in 2003 and presented to use for dry eye disease treatment.
📊
Key Findings & Data:To date, it was shown by randomized placebo controlled double-blinded studies that topical cyclosporine can significantly improve symptoms, ocular surface disease index scores, ocular surface staining scores, and tear film functions in moderate to severe eye disease.
💡
Conclusion & Impact:There isa need for better designed randomized placebo controlled double-blinded studies in order to find out the type of dry eye inwhich topical cyclosporine is the most effective, optimum dose, and treatment duration
🔬Design:Research Article
📍Scope:2003 Verileri
⚙️Variables:Domain Parameters

Abstract

Cyclosporine has been used successfully as a systemic immunomodulator for more than twenty years. 0.05% topical formulation has been approved by FDA in 2003 and presented to use for dry eye disease treatment. To date, it was shown by randomized placebo controlled double-blinded studies that topical cyclosporine can significantly improve symptoms, ocular surface disease index scores, ocular surface staining scores, and tear film functions in moderate to severe eye disease. There isa need for better designed randomized placebo controlled double-blinded studies in order to find out the type of dry eye inwhich topical cyclosporine is the most effective, optimum dose, and treatment duration

Özet

Siklosporin 20 yılı aşkın süredir sistemik immünmodülatör ilaç olarak başarı ile kullanılmaktadır. %0.05'lik topikal formülasyonu 2003 yılında FDA onayı alarak kuru göz hastalığının tedavisinde kullanıma sunulmuştur. Şimdiye kadar yapılan randomize plasebo kontrollü çift kör çalışmalarda topikal siklosporinin orta-ileri evre kuru göz hastalığında semptomlarda, oküler yüzey hastalık skorlarında, oküler yüzey boyanma skorlarında ve gözyaşı fonksiyonlarında anlamlı iyileşmeye yol açtığıortaya konulmuştur. Topikal siklosporinin hangi kuru göz tipinde en iyi etkinlik gösterdiğini, optimum doz ve tedavi süresinitayin etmek için daha iyi dizayn edilmiş plasebo kontrollü çift kör randomize çalışmalara ihtiyaç vardır

🔖

Cite This Article

ŞAHİN, A. (2016). Topical Cyclosporine in The Treatment of Dry Eye. MN Oftalmoloji, Cilt: 23 - Sayı: 1, 32–39. https://ajindex.com/articles/296739

References (19)

  1. Johnson ME, Murphy PJ. Changes in the tear film and ocular surface from dry eye syndrome. Prog Retin Eye Res 2004;23:449-74
  2. Rolando M, Zierhut M. The ocular surface and tear film and their dysfunction in dry eye disease. Surv Ophthalmol 2001;45 Suppl 2(S203-10
  3. Stern ME, Beuerman RW, Fox RI, Gao J, Mircheff AK, Pflugfelder SC. The pathology of dry eye: the interaction between the ocular surface and lacrimal glands. Cornea 1998;17:584-9
  4. Schaumberg DA, Sullivan DA, Dana MR. Epide mio - logy of dry eye syndrome. Adv Exp Med Biol 2002; 506:989-98
  5. Jie Y, Xu L, Wu YY, Jonas JB. Prevalence of dry eye among adult Chinese in the Beijing Eye Study. Eye 2008
  6. Schaumberg DA, Sullivan DA, Buring JE, Dana MR. Prevalence of dry eye syndrome among US women. Am J Ophthalmol 2003;136:318-26
  7. McCarty CA, Bansal AK, Livingston PM, Stanislavsky YL, Taylor HR. The epidemiology of dry eye in Mel - bourne, Australia. Ophthalmology 1998;105:1114-9
  8. The epidemiology of dry eye disease: report of the Epidemiology Subcommittee of the International Dry Eye WorkShop (2007). Ocul Surf 2007;5:93-107
  9. Lemp MA. Epidemiology and classification of dry eye. Adv Exp Med Biol 1998;438:791-803
  10. Mertzanis P, Abetz L, Rajagopalan K, et al. The relative burden of dry eye in patients' lives: comparisons to a U.S. normative sample. Invest Ophthalmol Vis Sci 2005;46:46-50
  11. Pflugfelder SC. Prevalence, burden, and pharmacoeconomics of dry eye disease. Am J Manag Care 2008;14:S102-6
  12. Yu J, Asche CV, Fairchild CJ. The economic burden of dry eye disease in the United States: a decision tree analysis. Cornea 2011;30:379-87
  13. Stern ME, Gao J, Siemasko KF, Beuerman RW, Pflug - fel der SC. The role of the lacrimal functional unit in the pathophysiology of dry eye. Exp Eye Res 2004;78:4 09-16
  14. Baudouin C. The pathology of dry eye. Surv Ophthalmol 2001;45 (Suppl 2):211-20
  15. Donnenfeld E, Pflugfelder SC. Topical ophthalmic cyclosporine: pharmacology and clinical uses. Surv Ophthalmol 2009;54:321-38
  16. Halloran PF, Kung L, Noujaim J. Calcineurin and the biological effect of cyclosporine and tacrolimus. Transplant Proc 1998;30:2167-70
  17. Fruman DA, Klee CB, Bierer BE, Burakoff SJ. Calcineurin phosphatase activity in T lymphocytes is inhibited by FK 506 and cyclosporin A. Proc Natl Acad Sci U S A 1992;89:3686-90
  18. Winslow MM, Neilson JR, Crabtree GR. Calcium signalling in lymphocytes. Curr Opin Immunol 2003; 15:299-307
  19. Horsley V, Pavlath GK. NFAT: ubiqu